Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc (PBYI) Stock: Do Analysts Think You Should Sell?
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Articles with Puma Biotechnology
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Supernus, Puma Among 5 Big Biotech Stock Winners, Losers Monday | Stock News & Stock Market Analysis - IBD
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Inc (PBYI) Stock: Do Analysts Think You Should Sell?
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
PBYI Stock Forecast, Price & News (Puma Biotechnology)
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotech News, Puma Biotech Quote, PBYI Quote - StreetInsider.com
Puma Biotechnology falls more than 20%
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
